Form 4: Fulgent Genetics' Chief Scientific Officer Gao Hanlin Reports Tax Withholding Transaction
SEC Form 4 Filing
Fulgent Genetics' Chief Scientific Officer, Gao Hanlin, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On July 26, 2024, Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported a transaction involving common stock.
- 1,154 shares were withheld to satisfy tax obligations related to the vesting of restricted stock units granted on November 7, 2022.
- The price per share for the transaction was $23.66.
- Following the transaction, Gao Hanlin beneficially owns 925,234 shares of Fulgent Genetics.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to tax obligations, and does not inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a standard tax withholding procedure related to equity compensation.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it relates to tax obligations from existing equity grants.
Key Dates
| Date | Description |
|---|---|
| November 7, 2022 | Date of grant of restricted stock units that led to the tax withholding. |
| November 9, 2022 | Original report of the restricted stock unit grant on Form 4. |
| July 26, 2024 | Date of the transaction (tax withholding). |
| July 30, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.